BioTech IP Review

Semaglutide in Medical Therapy

  • Assignee: Novo Nordisk A/S
  • Filed: August 30, 2024
  • Patent Granted: May 13, 2025
  • Publication Number: US20240415935 (application) / US12,295,988 (grant)
  • Inventors: Lars Holm Damgaard, Soeren Oestergaard Hardt-Lindberg, Thomas Hansen

What This Patent Covers

This patent protects the use of semaglutide — a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist — in specific medical therapy applications. Semaglutide is a cornerstone molecule for Novo Nordisk’s blockbuster drugs:

  • Ozempic® (for type 2 diabetes)
  • Wegovy® (for obesity and weight management)
  • Rybelsus® (oral GLP-1 formulation)

The patent covers methods of treatment and therapeutic uses of semaglutide in managing metabolic conditions, including:

  • Type 2 diabetes mellitus — improving glycemic control
  • Obesity and weight-related therapy
  • Potential related metabolic and cardiovascular indications where GLP-1 receptor modulation provides clinical benefit

Because semaglutide and its formulations have been foundational to Novo’s revenue growth, the U.S. patent enhances the company’s intellectual property protection into 2025, defending against generics and biosimilars in key markets.

Why It’s Important

• Core Blockbuster Product Protection

Semaglutide-based drugs have been among the top revenue generators for Novo Nordisk, especially for diabetes and obesity therapy markets worth tens of billions annually. Protecting this molecule’s uses helps sustain sales of Ozempic, Wegovy, and related products.

• Defense Against Generics

Even as some patent rights face challenges globally, new patent grants like US 12,295,988 bolster exclusivity in major markets like the United States, slowing competitor entry and preserving pricing power. (Global courts have also upheld semaglutide compound patents in China in late 2025.)

• Foundation for Expanded Indications

The broader therapeutic claims in this patent help Novo pursue label expansions (e.g., metabolic and cardiovascular indications) and defend those uses against legal challenges — crucial for long-term product strategy.

Summary

U.S. Patent No. 12,295,988, granted to Novo Nordisk A/S, secures commercial protection for semaglutide therapeutic applications — the molecule underlying multiple blockbuster diabetes and obesity drugs. Its importance lies in sustaining market exclusivity, defending against generic competition, and enabling continued global revenue from some of Novo’s most valuable products.

Leave a comment